Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

Masakazu Ichinose, Ayako Takizawa, Toshiyasu Izumoto, Yusuke Tadayasu, Alan L Hamilton, Christina Kunz, Yoshinosuke Fukuchi, Masakazu Ichinose, Ayako Takizawa, Toshiyasu Izumoto, Yusuke Tadayasu, Alan L Hamilton, Christina Kunz, Yoshinosuke Fukuchi

Abstract

Background: Olodaterol is a novel long-acting β2-agonist with proven ≥24-hour duration of action in preclinical and clinical studies.

Objective: This randomized, double-blind, placebo-controlled, parallel-group study evaluated the dose response of once-daily (QD) olodaterol based on bronchodilator efficacy, safety, and pharmacokinetics over 4 weeks in Japanese patients with chronic obstructive pulmonary disease (COPD).

Methods: All eligible patients were randomized to receive 2 µg, 5 µg, or 10 µg of olodaterol or placebo for 4 weeks via the Respimat Soft Mist inhaler. The primary end point was the change from baseline in trough forced expiratory volume in 1 second (FEV1) after 4 weeks of olodaterol treatment. Secondary end points included trough FEV1 after 1 week and 2 weeks of treatment, FEV1 area under the curve from 0 hour to 3 hours (AUC(0-3)), peak FEV1 from 0 hour to 3 hours (peak FEV1), and corresponding forced vital capacity (FVC) responses. Rescue medication use, COPD symptoms, physician global evaluation, pharmacokinetics, and safety were also assessed.

Results: A total of 328 patients with COPD were randomized to receive treatment. All olodaterol doses assessed in the study showed statistically significant increases in trough FEV1 compared to placebo at Day 29 (P<0.0001). Mean increases in peak FEV1 and FEV1 AUC(0-3) compared to placebo were also significant (P<0.0001). A clear dose-response relationship was observed across all treatment groups. FVC responses (trough and FVC AUC(0-3)) supported FEV1 outcomes. All doses of olodaterol were well tolerated, and no safety concerns were identified.

Conclusion: QD olodaterol demonstrated 24-hour bronchodilator efficacy and was well tolerated in Japanese patients with COPD.

Trial registration: ClinicalTrials.gov: NCT00824382.

Keywords: dose-finding; once-daily; plasma concentration; pulmonary function; trough FEV1; trough FVC.

Figures

Figure 1
Figure 1
Study design: 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Abbreviation: QD, once daily.
Figure 2
Figure 2
CONSORT diagram illustrating participant flow. Abbreviations: QD, once daily; AE, adverse event; CONSORT, Consolidated Standards of Reporting Trials.
Figure 3
Figure 3
Adjusted mean trough FEV1 (A) and FVC (B) responses (± standard error) at Weeks 1, 2, and 4 of olodaterol and placebo treatment. Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Figure 4
Figure 4
Mean FEV1 (A and B) and FVC (C and D) responses from −10 minutes to 3 hours on Day 1 (first administration) and Week 4. Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; min, minutes.
Figure 5
Figure 5
Mean plasma concentration–time profiles for olodaterol. Notes: Plasma concentrations after olodaterol 2 µg inhalation were too low to be quantified in most patients; therefore, mean plasma concentration profiles are not displayed.
Figure 6
Figure 6
Dose-normalized steady-state maximum concentrations (A) and AUC0–1 (B) of olodaterol. Note: Plasma concentrations after olodaterol 2 µg inhalation in most patients were below the limit of quantification; therefore, a gMean was not calculated. Abbreviations: gMean, geometric mean; Cmax,ss,norm, maximum measured concentration of olodaterol in plasma, steady-state, dose-normalized; AUC0–1,ss,norm, area under the curve from 0 hour to 1 hour, steady-state, dose-normalized.

References

    1. Guerra S. Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2009;9(5):409–416.
    1. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, GOLD Scientific ommittee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276.
    1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. [Accessed February 17, 2015]. Updated 2013. Available from: .
    1. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997;10(4):815–821.
    1. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
    1. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest. 2012;142(5):1104–1110.
    1. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441.
    1. Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20(4):1410–1414.
    1. Cazzola M, Matera MG, Lötvall J. Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14(7):775–783.
    1. Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(5):596–605.
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
    1. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224.
    1. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666–672.
    1. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050.
    1. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714.
    1. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645.
    1. Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.
    1. Lange P, Aumann J-L, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. 2014;4:196.
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
    1. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers J-WJ, Herings RMC. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398–1405.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever